Oncolytics Biotech Inc美股招股说明书(2026-04-06版)

$75,000,000 Common Stock We have entered into an Open Market Sale AgreementSM(the “Sales Agreement”) with Jefferies LLC (“Jefferies”) relating toshares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. Inaccordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offeringprice of up to $75,000,000 from time to time through or to Jefferies, acting as sales agent or principal. Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made by anymethod deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the U.S. Securities Act of 1933, as amended (the“Securities Act”). Subject to the terms of the Sales Agreement, Jefferies is not required to sell any specific number or dollar amount ofshares of our common stock, but will use commercially reasonable efforts consistent with its normal trading and sales practices. Thereis no arrangement for funds to be received in any escrow, trust or similar arrangement. Jefferies will be entitled to compensation at a commission rate up to 3.0% of the gross proceeds of any shares of common stocksold under the Sales Agreement. In connection with the sale of our common stock on our behalf, Jefferies will be deemed to be an“underwriter” within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwritingcommissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies against certain liabilities,including liabilities under the Securities Act and the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). See“Plan of Distribution” beginning on page S-8 for additional information. Our common stock is listed on the Nasdaq Capital Market under the symbol “ONCY.” On April 2, 2026, the last reported saleprice of our common stock on the Nasdaq Capital Market was $0.96 per share. We are a “smaller reporting company” as defined under the federal securities laws and, as such, we have elected to comply withcertain reduced reporting requirements for this prospectus supplement and may elect to do so in future filings. See “ProspectusSupplement Summary—Implications of Being a Smaller Reporting Company.” Investing in our common stock involves a high degree of risk. Before making an investment decision, please read theinformation under the heading “Risk Factors” beginning on page S-3 of this prospectus supplement, on page 5 of theaccompanying prospectus and in the documents incorporated by reference into this prospectus supplement. Neither the U.S. Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved ordisapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation tothe contrary is a criminal offense. Jefferies Prospectus Supplement dated April 6, 2026 TABLE OF CONTENTS Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTS-iiiPROSPECTUS SUPPLEMENT SUMMARYS-1RISK FACTORSS-3CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSS-5USE OF PROCEEDSS-6DILUTIONS-7PLAN OF DISTRIBUTIONS-8LEGAL MATTERSS-9EXPERTSS-9WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCES-10 Prospectus ABOUT THIS PROSPECTUS1CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS2WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE3THE COMPANY4RISK FACTORS5USE OF PROCEEDS6DESCRIPTION OF CAPITAL STOCK7DESCRIPTION OF WARRANTS12DESCRIPTION OF PURCHASE CONTRACTS13DESCRIPTION OF UNITS14GLOBAL SECURITIES15PLAN OF DISTRIBUTION19LEGAL MATTERS21EXPERTS21 You should rely only on the information contained or incorporated by reference in this prospectus supplement and theaccompanying prospectus or any free writing prospectus we may authorize to be delivered or made available to you. Neither we norJefferies have authorized anyone to provide information or to make any representations different from those contained or incorporatedby reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus we may authorize to bedelivered or made available to you. Neither we nor Jefferies take any responsibility for, or can provide any assurance as to thereliability of, any information other than the information contained or incorporated by reference in this prospectus supplement, theaccompanying prospectus or any free writing prospectus prepared we may authorize to be delivered or made available to you. Thisprospectus supplement, the accompanying prospectus or any applicable free writing prospectus is not an offer to sell or solicitation ofan offer to buy our shares of common stock in any circumstances under which the offer or solicitation is unlawful. Neither we norJefferies are offering to sell our shares of common stock in any jurisdiction where an offer or sale is not permitted. The informatio